Cantor Fitzgerald Comments on RARE FY2025 Earnings
Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Ultragenyx Pharmaceutical in a ...
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- A/S (Nasdaq: ASND) ...
FY2024 Earnings Estimate for RARE Issued By Leerink Partnrs
Stock analysts at Leerink Partnrs lifted their FY2024 EPS estimates for Ultragenyx Pharmaceutical in a report released on ...
News Medical17d
An Overview of X-Linked Disorders and X Chromosome Aneuploidies
4 Hypophosphatemia occurs when there are genetic ... 5 Mohr-Tranebjaerg Syndrome (MTS) is a rare X-linked neurodegenerative disorder that causes early-onset hearing loss, gradual and progressive ...
Frontiers21d
Case report: Prolonged and severe hungry bone syndrome after parathyroidectomy in X-linked hypophosphatemia
This condition can be a complication of X-linked hypophosphatemia (XLH), a rare genetic disease characterized by renal phosphate loss and consequent hypophosphatemia. Parathyroidectomy is considered ...
pharmaphorum6d
AI technology: A game-changer for rare disease diagnosis
Last year, five possible cases of X-Linked Hypophosphatemia (XLH) were identified via MendelScan technology and all of these cases were moved forward by clinical reviewers. This is a highly ...
Hosted on MSN19d
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
Ultragenyx Pharmaceutical RARE announced that the European Commission (EC) has expanded the eligible patient population for one of its marketed products, Evkeeza (evinacumab), an ANGPTL3 inhibitor.